At the last check on Thursday, PhenomeX Inc.’s (NASDAQ:CELL) stock traded at $0.99. The average number of shares traded per day over the past five days has been 848,501 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0011 gain in that time frame. In the last twenty days, the average volume was 1,328,135, while in the previous 50 days, it was 1,760,196.
Since last month, CELL stock rose 6.06%. Shares of the company fell to $0.9312 on 08/25/23, the lowest level in the past month. A 52-week high of $3.65 was reached on 01/03/23 after having rallying from a 52-week low of $0.38. Since the beginning of this year, CELL’s stock price has dropped by -62.95% or -$1.6919, and marked a new high 1 time. However, the stock has declined by -72.80% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
The stock’s beta is 0.89. Besides these, the trailing price-to-sales (P/S) ratio of 1.37, the price-to-book (PB) ratio of 0.88.
Financial Health
In the three months ended June 29, PhenomeX Inc.’s quick ratio stood at 1.30, while its current ratio was 2.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 64.70% percent. Based on annual data, CELL earned $53.78 million in gross profit and brought in $78.59 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -60.60%. Return on equity (ROE) for the past 12 months was -87.50%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. CELL’s revenue fell -36.4% to $18.52 million during the quarter, while net income inched up to $14.04 million. While analysts expected PhenomeX Inc. to report -$0.33 quarterly earnings, the actual figure was -$0.51 per share, beating the consensus estimate by -54.50%. During the quarter, the company generated -$41.88 million in EBITDA. The liabilities of PhenomeX Inc. were 67.05 million at the end of its most recent quarter ended June 29, and its total debt was $28.97 million. The value of shareholders’ equity is $99.3 million.
Technical Picture
This quick technical analysis looks at PhenomeX Inc.’s (CELL) price momentum. With a historical volatility rate of 3.43%, the RSI 9-day stood at 72.44% on 20 September.
With respect to its five-day moving average, the current PhenomeX Inc. price is up by +0.11% percent or $0.0011. At present, CELL shares trade +5.57% above its 20-day simple moving average and -15.55% percent below its 100-day simple moving average. However, the stock is currently trading approximately +58.43% above its SMA50 and -68.63% below its SMA200.
Stochastic coefficient K was 85.23% and Stochastic coefficient D was 86.32%, while ATR was 0.0166. Given the Stochastic reading of 76.71% for the 14-day period, the RSI (14) reading has been calculated as 69.62%.
Analyst Ratings
PhenomeX Inc. (CELL) has been rated Hold by analysts. According to 0 brokerage firms, CELL is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate PhenomeX Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $1.00, the current consensus forecast for the stock is $1.00 – $1.00. Based on these forecasts, analysts predict PhenomeX Inc. (CELL) will achieve an average price target of $1.00.
